These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 38294337)

  • 41. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
    Ristic S; Collober-Maugeais C; Cressier F; Tang P; Pecher E
    Diabetes Obes Metab; 2007 Jul; 9(4):506-11. PubMed ID: 17587393
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety Assessment of Glucose-Lowering Drugs and Importance of Structured Education during Ramadan: A Systematic Review and Meta-Analysis.
    Shiju R; Akhil A; Thankachan S; Tuomilehto J; Al Arouj M; Bennakhi A
    J Diabetes Res; 2022; 2022():3846253. PubMed ID: 35242880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Ramadan fasting on glycaemic parameters & body mass index in type II diabetic patients: A meta-analysis.
    Aydin N; Kul S; Karadağ G; Tabur S; Araz M
    Indian J Med Res; 2019 Dec; 150(6):546-556. PubMed ID: 32048618
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
    Hassanein M; Echtay A; Hassoun A; Alarouj M; Afandi B; Poladian R; Bennakhi A; Nazar M; Bergmans P; Keim S; Hamilton G; Azar ST
    Int J Clin Pract; 2017 Oct; 71(10):. PubMed ID: 28851109
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ramadan fasting in diabetes patients on insulin pump therapy augmented by continuous glucose monitoring: an observational real-life study.
    Khalil AB; Beshyah SA; Abu Awad SM; Benbarka MM; Haddad M; Al-Hassan D; Kahwatih M; Nagelkerke N
    Diabetes Technol Ther; 2012 Sep; 14(9):813-8. PubMed ID: 22827507
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
    Landman GW; de Bock GH; van Hateren KJ; van Dijk PR; Groenier KH; Gans RO; Houweling ST; Bilo HJ; Kleefstra N
    PLoS One; 2014; 9(2):e82880. PubMed ID: 24533045
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impact of provision of optimum diabetes care on the safety of fasting in Ramadan in adult and adolescent patients with type 1 diabetes mellitus.
    Alawadi F; Alsaeed M; Bachet F; Bashier A; Abdulla K; Abuelkheir S; Rashid F; Abdulaziz Bin Hussain A; Abdelgadir E; Alsayyah F; Elsayed M; Hassanein M
    Diabetes Res Clin Pract; 2020 Nov; 169():108466. PubMed ID: 32971155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Glargine insulin/gliclazide MR combination therapy is more effective than premixed insulin monotherapy in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs.
    Zhou J; Zheng F; Guo X; Yang H; Zhang M; Tian H; Guo L; Li Q; Mo Y; Jia W
    Diabetes Metab Res Rev; 2015 Oct; 31(7):725-33. PubMed ID: 25952634
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Implementing an optimized glucose-lowering strategy with a novel once daily modified release gliclazide formulation.
    Leiter LA; Shestakova MV; Trubitsyna NP; Piletič M; Satman I
    Diabetes Res Clin Pract; 2016 Feb; 112():50-56. PubMed ID: 26653612
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Gliclazide modified release: results of a 2-year study in patients with type 2 diabetes.
    Drouin P; Standl E;
    Diabetes Obes Metab; 2004 Nov; 6(6):414-21. PubMed ID: 15479217
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study.
    Filozof C; Gautier JF
    Diabet Med; 2010 Mar; 27(3):318-26. PubMed ID: 20536495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A systematic review on efficacy and safety of the current hypoglycemic agents in patients with diabetes during Ramadan fasting.
    Rashid F; Abdelgadir E
    Diabetes Metab Syndr; 2019; 13(2):1413-1429. PubMed ID: 31336501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of empagliflozin in people with type 2 diabetes during Ramadan fasting.
    Yousuf S; Ahmedani MY
    Diabetes Metab Syndr; 2022 Nov; 16(11):102633. PubMed ID: 36279701
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validation of the new IDF-DAR risk assessment tool for Ramadan fasting in patients with diabetes.
    Mohammed N; Buckley A; Siddiqui M; Al Ahmed S; Afandi B; Hassanein M; Lessan N; Suliman M
    Diabetes Metab Syndr; 2023 Apr; 17(4):102754. PubMed ID: 36989583
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes.
    Vilar L; Canadas V; Arruda MJ; Arahata C; Agra R; Pontes L; Montenegro L; Vilar CF; Silva LM; Albuquerque JL; Gusmão A
    Arq Bras Endocrinol Metabol; 2010 Mar; 54(3):311-8. PubMed ID: 20520962
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
    Seufert J; Pegelow K; Bramlage P
    Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of metformin plus gliclazide versus metformin plus glimepiride on cardiovascular risk factors in patients with type 2 diabetes mellitus.
    Hassan MH; Abd-Allah GM
    Pak J Pharm Sci; 2015 Sep; 28(5):1723-30. PubMed ID: 26408873
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of insulin glargine and glimepiride in subjects with Type 2 diabetes before, during and after the period of fasting in Ramadan.
    Salti I;
    Diabet Med; 2009 Dec; 26(12):1255-61. PubMed ID: 20002478
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Patterns of Diabetes Care Among People with Type 1 Diabetes During Ramadan: An International Prospective Study (DAR-MENA T1DM).
    Al Awadi FF; Echtay A; Al Arouj M; Sabir Ali S; Shehadeh N; Al Shaikh A; Djaballah K; Dessapt-Baradez C; Omar Abu-Hijleh M; Bennakhi A; El Hassan Gharbi M; El Sayed El Hadidy K; Abdul Kareem Khazaal F; Hassanein MM
    Adv Ther; 2020 Apr; 37(4):1550-1563. PubMed ID: 32144714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.